Xeris Biopharma Holdings, Inc. (XERS) - Form 8-K Summary
Business Context and Reporting Period
Xeris Biopharma Holdings, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 6, 2026. The filing serves to announce the Company's results of operations and business highlights for the three and six months ended June 30, 2026. The Company is listed on the Nasdaq Global Select Market under the symbol XERS and is classified as an emerging growth company.
Financial Metrics
This Form 8-K is a notification filing and does not contain specific financial data points within its text. The filing references a press release (Exhibit 99.1) for detailed metrics. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reported periods.
Material Changes
The filing does not detail specific material changes in financial condition or operations within the body of the report. Investors are directed to the attached press release for a comparison of results versus prior comparable periods.
Guidance, Outlook, and Risks
The filing does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. Such information is contained exclusively in the referenced press release (Exhibit 99.1).
Key Facts for Investor Verification
- Verify the specific revenue and net loss figures for the three and six months ended June 30, 2026, by reviewing Exhibit 99.1 (Press Release).
- Confirm the Company's cash position and burn rate as disclosed in the referenced press release to assess liquidity runway.
- Review the press release for any updates on clinical trial progress or regulatory milestones, which are typical drivers for biopharma valuations.
- Note that the information in this 8-K is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability for the referenced data.